Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung, a validating test for the diagnosis of lung cancer. The company's molecular diagnostic products are based on its proprietary methylation technology, which is based on a biological phenomenon called DNA methylation. The company also offers Epi BiSKit, a pre-analytical kit for the preparation of bisulfite-converted DNA, and HCCBloodTest for the detection of hepatocellular carcinoma (HCC). Epigenomics is headquartered in Berlin, Germany.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Epigenomics AG
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Epigenomics AG Company Overview
- Epigenomics AG Company Snapshot
- Epigenomics AG Pipeline Products and Ongoing Clinical Trials Overview
- Epigenomics AG - Pipeline Analysis Overview
- Business Description
- Epigenomics AG - Key Facts
- Epigenomics AG - Major Products and Services
- Epigenomics AG Pipeline Products by Development Stage
- Epigenomics AG Ongoing Clinical Trials by Trial Status
- Epigenomics AG Pipeline Products Overview
- Biomarker PITX2 - Prostate Cancer Prognosis
- Biomarker PITX2 - Prostate Cancer Prognosis Product Overview
- Blood - Based Lung Cancer Test
- Blood - Based Lung Cancer Test Product Overview
- Epi proColon 1.0
- Epi proColon 1.0 Product Overview
- Next-Generation Colorectal Cancer Test
- Next-Generation Colorectal Cancer Test Product Overview
- Next-Generation Colorectal Cancer Test Clinical Trial
- NGS Panel - Bladder Cancer
- NGS Panel - Bladder Cancer Product Overview
- NGS Panel - Breast Cancer
- NGS Panel - Breast Cancer Product Overview
- NGS Panel - Colon Cancer
- NGS Panel - Colon Cancer Product Overview
- NGS Panel - Lung Cancer
- NGS Panel - Lung Cancer Product Overview
- NGS Panel - Ovarian Cancer
- NGS Panel - Ovarian Cancer Product Overview
- NGS Panel - Prostate Cancer
- NGS Panel - Prostate Cancer Product Overview
- Epigenomics AG - Key Competitors
- Epigenomics AG - Key Employees
- Epigenomics AG - Key Employee Biographies
- Epigenomics AG - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Epigenomics AG, Recent Developments
- Jan 27, 2023: Epigenomics Announces Resignation of the Chairman of the Supervisory Board Heino von Prondzynski
- Dec 14, 2022: Epigenomics licenses protein biomarker technology for blood-based colorectal cancer test
- Dec 14, 2021: Supervisory Board of Epigenomics AG appoints Jens Ravens as Chief Financial Officer
- Nov 29, 2019: New micro-simulation study in cancer medicine finds Epi proColon provides clinically meaningful reductions in incidence and mortality of colorectal cancer
- Nov 19, 2019: Epigenomics reports financial results for the first nine months 2019
- Aug 07, 2019: Epigenomics highlights operational achievements and reports financial results for first six months 2019
- Jul 24, 2019: Study published in American Health Drug Benefits suggests that non-invasive screening methods, including Epi proColon, could be a cost-effective option to help achieve target U.S. colorectal cancer screening rates
- Jul 11, 2019: Epigenomics receives MedTech Outlook's 2019 top 10 in-vitro diagnostics award
- Jun 17, 2019: New clinical data support the utility of Epi proColon blood test for colorectal cancer screening in patients with Lynch Syndrome, the most common hereditary CRC Syndrome
- May 19, 2019: New report shows CRC screening rates increased when a medically underserved population is offered Epi proColon Blood Test
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Epigenomics AG Pipeline Products and Ongoing Clinical Trials Overview
- Epigenomics AG Pipeline Products by Equipment Type
- Epigenomics AG Pipeline Products by Indication
- Epigenomics AG Ongoing Clinical Trials by Trial Status
- Epigenomics AG, Key Facts
- Epigenomics AG, Major Products and Services
- Epigenomics AG Number of Pipeline Products by Development Stage
- Epigenomics AG Pipeline Products Summary by Development Stage
- Epigenomics AG Ongoing Clinical Trials by Trial Status
- Epigenomics AG Ongoing Clinical Trials Summary
- Biomarker PITX2 - Prostate Cancer Prognosis - Product Status
- Biomarker PITX2 - Prostate Cancer Prognosis - Product Description
- Blood - Based Lung Cancer Test - Product Status
- Blood - Based Lung Cancer Test - Product Description
- Epi proColon 1.0 - Product Status
- Epi proColon 1.0 - Product Description
- Next-Generation Colorectal Cancer Test - Product Status
- Next-Generation Colorectal Cancer Test - Product Description
- Next-Generation Colorectal Cancer Test - Prospective, Multi-center Observational Study for the Clinical Validation of the Next Generation Test for Blood-based Screening of Colorectal Cancer
- NGS Panel - Bladder Cancer - Product Status
- NGS Panel - Bladder Cancer - Product Description
- NGS Panel - Breast Cancer - Product Status
- NGS Panel - Breast Cancer - Product Description
- NGS Panel - Colon Cancer - Product Status
- NGS Panel - Colon Cancer - Product Description
- NGS Panel - Lung Cancer - Product Status
- NGS Panel - Lung Cancer - Product Description
- NGS Panel - Ovarian Cancer - Product Status
- NGS Panel - Ovarian Cancer - Product Description
- NGS Panel - Prostate Cancer - Product Status
- NGS Panel - Prostate Cancer - Product Description
- Epigenomics AG, Key Employees
- Epigenomics AG, Key Employee Biographies
- Epigenomics AG, Subsidiaries
- Glossary
- Epigenomics AG Pipeline Products by Equipment Type
- Epigenomics AG Pipeline Products by Development Stage
- Epigenomics AG Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- F. Hoffmann-La Roche Ltd
- Bayer AG
- Thermo Fisher Scientific Inc
- Qiagen Aarhus AS
- Becton Dickinson and Co
- bioMerieux SA
